Aethlon Medical furnished an updated investor presentation from North Immunology, its merger target under the September 17, 2026 agreement. It details the NOR-101 IL-13 x IL-18 bispecific antibody, Phase 1a start in Q1 2027, and an anticipated $180M private placement.
AEMD · Aethlon Medical Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Aethlon Medical agreed to merge with North Immunology, a two-step transaction expected to close in first calendar quarter 2027. The six-month net loss rose to $4,165,000, while cash was $6,486,639 as of September 30, 2026.
Aethlon Medical entered a merger agreement with North Immunology on September 17, 2026 and implemented workforce reductions. Cash was approximately $6.5 million as of September 30, 2026; quarterly operating expenses rose 77.2% to approximately $2.7 million.
Aethlon Medical, Inc. increased authorized common stock from 20,000,000 shares to 200,000,000 shares, following stockholder approval on October 1, 2026; the amendment became effective on October 7, 2026.
Aethlon Medical, Inc. stockholders did not approve a proposal to authorize 20,000,000 preferred shares because 204,122 votes in favor fell below the required 355,569; the Articles of Incorporation were not amended.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Feb 12, 2026TL;DR. Aethlon advanced its Australian oncology trial and research programs, maintained Nasdaq compliance, and reduced year-to-date operating expenses. The quarter still had higher operating expenses and a larger operating loss, while cash adequacy and investigational-device risks remain concerns; SLAMB also requires regulatory submission and is not expected to benefit the current or next trial.
- + Cohort 2 of the Australian oncology trial is progressing after Cohort 1 showed favorable directional improvements in extracellular vesicle and immune cell numbers.
- + Year-to-date operating expenses declined 26.9% through continued cost optimization.
- + Long COVID research findings were published on bioRxiv and submitted for peer review.
- + The Hemopurifier may provide a pipeline within a single device.
- + Stavro is evaluating Hemopurifier compatibility with the SLAMB system, which may support broader future use without dialysis equipment or a supervising nephrologist.
- + The company maintained Nasdaq listing compliance and resolved all prior compliance matters.
- − Fiscal Q3 operating expenses rose 13.6% and the operating loss increased to $2.06 million from $1.81 million.
- − Interest income declined to $44,000 from $60,000 in the prior-year quarter.
- − Cash may not support operations for the next 12 months without additional financing, and capital may be unavailable or unfavorable.
- − The Hemopurifier remains investigational, with its safety and effectiveness not established.
- − The SLAMB system is not FDA-approved and would require a regulatory submission and additional treatments with the two systems.
- − SLAMB compatibility work is not expected to benefit the current or next trial.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AEMD
this stock
Aethlon Medical Inc
|
$7.78M | — | -100.0% | — | 2.7% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 31
Aethlon Medical furnished an updated investor presentation from North Immunology, its merger target under the September 17, 2026 agreement. It details the NOR-101 IL-13 x IL-18 bispecific antibody, Phase 1a start in Q1 2027, and an anticipated $180M private placement.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AEMD | -13.3% | -6.7% | -59.8% | -11.0% | -65.1% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -7.8% | -0.5% | -54.2% | -5.8% | -70.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.